Loading stock data…
Senti Biosciences Holdings (SNTI)
$1.11+0.02 (+1.83%)
After Hours$1.09-0.02 (-1.80%)· Last close Jun 29
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Senti Biosciences Holdings, Inc. in the Healthcare sector is trading at $1.11 with a market capitalization of $30M. Wall Street consensus targets $13.00 (3 analysts), implying a +1071.2% move over the next 12 months. The stock is currently near its 52-week low of $0.77, remaining 11.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1071.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $16,000↓ | $22,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.50M↑ | -$13.58M↑ | -$16.95M↓ | -$16.80M↓ | -$16.40M |
| Net Income | -$4.22M↑ | -$14.47M↑ | -$18.13M↓ | -$14.73M↓ | -$14.11M |
Peer Comparison
JNJUNHPFE
Fundamentals
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utili...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2009.63%
Volume
Today's trading volume
126,591